BioSpace News Archive

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three months ended March 31, 2021. Highlights of and subsequent to the first quarter of 2021 include: The Company’s total revenue in the first quarter of 2021

Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the “Company”) announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued and outstanding stock. The reverse stock split was completed with the state of Florida on March 12, 2020. FINRA’s processing was the last step necessary to fully effectuate the reverse split approved by shareholders in October of 2019. The Company’s common stock began trading on a split-adjusted ba

AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at Investor Summit Group’s Q2 Virtual Investor Summit taking place May 17-18, 2021.

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.

Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration

Dynavax Technologies Corporation (“Dynavax”) (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2026 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced results for the first quarter ended March 31, 2021 and provided a business update.

GO2 Foundation for Lung Cancer has launched a landmark initiative to identify the needs of the Small Cell Lung Cancer community.

Precision BioSciences, Inc. announced new in vivo data resulting from a preclinical research collaboration with investigators at the University of Pennsylvania presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting.

First quarter total revenue of $32.1 million, up 23 percent year-over-year; Software revenue of $26.3 million, up 11 percent year-over-year